David Keelen, MD
Pain Medicine · Frisco, TXNPI 1790088508
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,179 of the $34,836 with a category attached, or 66.5%. Saluda Medical Americas, Inc. accounts for 66.2% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $23,125, 3.1 times the $7,503 reported in 2019. Among pain medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $101.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$23K
- Flowonix Medical Incorporated$6K
- Collegium Pharmaceutical, Inc.$834
- Medtronic$765
- Forte Bio-pharma LLC$521
- AbbVie$351
- plus $3K from 33 others
Across 1 payment — averaging $163.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$163
What the payments were for
- Consulting fees$23,17967%
- Travel & lodging$4,94914%
- Food & beverage$6,70519%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$22,654
- Prometra II$6,429
- Nalocet$179
- Prolate$179
How this compares
$34,836 in reported general payments places this provider in the 90th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 45 | $65,933 |
| Xtampza ErOxycodone Myristate | 60 | $59,331 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 959 | $35,215 |
| OxycontinOxycodone Hcl | 49 | $30,684 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 439 | $18,123 |
| Oxycodone Hcl | 328 | $13,189 |
| SavellaMilnacipran Hcl | 14 | $11,508 |
| Fentanyl | 95 | $10,063 |
| MovantikNaloxegol Oxalate | 17 | $7,239 |
| Morphine Sulfate ErMorphine Sulfate | 202 | $6,821 |
| Hysingla ErHydrocodone Bitartrate | 11 | $5,434 |
| Doxepin Hcl | 12 | $5,275 |
| Gabapentin | 239 | $4,941 |
| Pregabalin | 261 | $4,725 |
| DayvigoLemborexant | 13 | $4,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er | $834 | $125,264105 claims |
| AbbVieSavella | $351 | $11,50814 claims |
| Eisai Inc.Dayvigo | $20 | $4,40013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Frisco
- Shamim BadiyanFrisco$24K
- Rahul MishraFrisco$22K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Candice BurnetteSugar Land$265K
- Ashley Bailey-ClassenFort Worth$244K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Anthony BergRockwall$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.